— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
Key highlights from Deere & Co.’s (DE) Q4 2024 earnings results
Deere & Company (NYSE: DE) reported its fourth quarter 2024 earnings results today. Worldwide net sales and revenues decreased 28% year-over-year to $11.14 billion. Net income was $1.24 billion, or
NVDA Earnings: Nvidia Q3 profit jumps, beats estimates
NVIDIA Corporation (NASDAQ: NVDA) on Wednesday reported a sharp increase in adjusted profit and revenue for the third quarter of 2025. Earnings also topped analysts' estimates. The tech firm’s revenues
Lowe’s Companies (LOW): A few points to note about the Q3 2024 performance
Shares of Lowe’s Companies, Inc. (NYSE: LOW) rose over 1% on Wednesday. The stock has gained 8% over the past three months. The company delivered better-than-expected earnings results for the